|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||35.36 - 36.04|
|52 Week Range||28.43 - 36.75|
|PE Ratio (TTM)||29.87|
|Forward Dividend & Yield||1.40 (3.92%)|
|1y Target Est||39.09|
AstraZeneca (AZN) wins the FDA approval for the label expansion of its marketed drug, Tagrisso, for first-line treatment of adult patients with locally-advanced or metastatic NSCLC.
U.S. regulators have expanded use of AstraZeneca's lung cancer drug Tagrisso to include initial treatment of patients with a specific genetic mutation, the company said on Wednesday. The latest Food and Drug Administration approval includes patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
Novartis AG (NVS) reported revenue of $12.9 billion and EPS (earnings per share) of $1.21 in 4Q17, a 4.8% rise in revenue compared to 4Q16. For 1Q18, analysts expect Novartis to see EPS of $1.28 on revenue of $12.6 billion.
Alcon, Novartis’s (NVS) eye care business, includes surgical products and vision care products. Alcon products are marketed in over 180 countries worldwide. Alcon is expected to report growth in revenue following increased demand for contact lenses and surgical products in 1Q18.
If a certain drug doesn't work to manufacturers' expectations, then the insurer either doesn't pay for it or gets a rebate.
In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter. In fiscal 2017, AndroGel generated revenue of $577 million, marking a ~14.5% decline YoY.
How far off is AstraZeneca PLC (LSE:AZN) from its intrinsic value? Using the most recent financial data, I am going to take a look at whether the stock is fairlyRead More...
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US today presented data from the Phase III OlympiAD trial, showing the final overall survival results for LYNPARZA® in metastatic breast cancer at the American Association for Cancer Research Annual Meeting in Chicago, April 14-18, 2018.
On April 5, 2018, Barclays (BCS) updated its recommendations for some leading US pharmaceutical companies. It downgraded its recommendation for Pfizer (PFE) from “overweight” to “equal weight,” and Barclays analyst Geoff Meacham cut his price target on Pfizer stock from $41 to $38. That day, Pfizer stock fell ~1.3% following the announcement of the rating downgrade.
Spectrum Pharmaceuticals' (SPPI) poziotinib shows encouraging results in preliminary analysis of data from phase II lung cancer study.
On April 9, 2018, Merck (MRK) stock rose ~4.4% in early trading and ~2.7% during the day. The highest price reached on April 9 was 7% higher than the stock’s April 8 closing price. Peers Bristol-Myers Squibb (BMY), AstraZeneca (AZN), and Roche (ROG) returned -0.08%, 0.24%, and 0.05%, respectively on April 9, and the SPDR S&P 500 ETF (SPY) rose ~1.1%. MRK accounts for ~0.65% of SPY’s total holdings.
GlaxoSmithKline (GSK) is a British multinational pharmaceutical company with headquarters in Brentford, Middlesex. The company classifies its business portfolio into three business segments: Pharmaceuticals, Vaccines, and Consumer Healthcare.
Ionis (IONS) inks a licensing deal with AstraZeneca per which the former will license IONIS-AZ6-2.5-LRx to AstraZeneca for the treatment of NASH.
Headquartered in London, AstraZeneca (AZN) is a pharmaceutical company with operations in over 100 countries. The company is involved in the research, development, and manufacture of drugs for both primary care and specialty care.
Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company that specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products.
Ionis Pharmaceuticals Inc. shares rose 3% premarket Monday, after the company unveiled a licensing deal with AstraZeneca PlC for a treatment for nonalcoholic steatohepatitis (NASH), or fatty liver. Ionis ...
Ionis Pharmaceuticals said on Monday it signed a licensing deal for its fatty liver disease treatment with AstraZeneca Plc that could land the company up to $300 million in milestone payments and royalties. ...
CARLSBAD, Calif., April 9, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that it has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca (AZN) following advancement of the drug into development. In conjunction with this milestone, global, science-led biopharmaceutical company AstraZeneca will pay a $30 million license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of IONIS-AZ6-2.5-LRx.
Pfizer (PFE) inks new CAR-T deal, AstraZeneca (AZN) provides positive regulatory updates and Lilly's (LLY) Cyramza shows survival benefit in liver cancer study
FibroGen (FGEN) is capitalizing on its extensive experience in fibrosis and hypoxia-inducible factor (or HIF) biology to advance a pipeline targeted for the treatment of anemia, fibrotic disease, cancer, and corneal blindness. Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200. FG-3019 is a fully human monoclonal antibody that inhibits the activity of connective tissue growth factor.
Here we discuss three emerging technologies, which the pharma/biotech industry has started adopting, albeit slowly. These are poised to transform the sector by saving time as well as cost.
LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Merck & Co., Inc. (NYSE: MRK ) ("Merck"). If you want access to this report all you ...